54126-58-8Relevant academic research and scientific papers
Synthesis and antiarrhythmic activity of new 1-[1-[2-[3-(alkylamino)-2-hydroxypropoxy]phenyl]vinyl]-1H-imidazoles and related compounds
Ogata,Matsumoto,Takahashi,Shimizu,Kida,Ueda,Kimoto,Haruna
, p. 1142 - 1149 (2007/10/02)
Various 1-[1-[2-[3-(alkylamino)-2-hydroxypropoxy]phenyl]vinyl]-1H-azoles were synthesized and investigated for β-adrenoceptor-blocking and antiarrhythmic activities. Although no compounds showed more potent β-blocking effects than propranolol in the isolated guinea pig right atria, many compounds exhibited significant antiarrhythmic effects against aconitine or ischemic arrhythmia in mice or dogs. 1-[2,5-Dichloro-6-[1-(1H-imidazol-1-yl)ethenyl]phenoxy]-3-[(1-methylethyl) amino]-2-propanol hydrochloride (48) (711389-S) was selected as a candidate for clinical evaluation in man, since its antiarrhythmic effects were superior to those of quinidine, disopyramide, or propranolol. Asymmetric synthesis of (R)-(+)- and (S)-(-)-48 is described, and it is proven that there is no stereospecificity in the antiarrhythmic effect of 48.
β1-Selective adrenoceptor antagonists: Examples of the 2-[4-[3-(substituted-amino)-2-hydroxypropoxy]phenyl]imidazole class
Baldwin,Denny,Hirschmann,Freedman,Ponticello,Gross,Sweet
, p. 950 - 957 (2007/10/02)
A series of 2-[4-[3-(substituted-amino)-2-hydroxypropoxy]phenyl]imidazoles is described. The compounds were investigated in vitro for β-adrenoceptor antagonism, and several examples were found to be selective for the β1-adrenoceptor. The structure-activity relationship exhibited by this series of compounds is discussed. (S)-2-[p-[3-[[2-(3,4-dimethoxyphenyl)ethyl]amino]-2-hydroxypropoxy]phenyl] -4-(2-thienyl)imidazole [(S)-13] was over 100 times more selective than atenolol for the β1-adrenergic receptor and has been selected for in-depth studies.
1-Substituted-amino-3-(4-furo[3,2-c]pyridinyloxy)-2-propanols
-
, (2008/06/13)
This invention provides new compounds of formula I, STR1 wherein R is alkyl of 3 to 7 carbon atoms or cycloalkyl of 3 to 7 carbon atoms, cycloalkyl of 3 to 7 carbon atoms monosubstituted by alkyl of 1 to 4 carbon atoms, α-dialkylpropynyl of 5 to 9 carbon atoms or α-dialkyl-allyl of 5 to 9 carbon atoms, hydroxyalkyl of 2 to 7 carbon atoms or phenoxyalkyl of 8 to 11 carbon atoms, the oxygen atom of the last two radicals being separated by at least two carbon atoms from the nitrogen atom to which R is bound, R1 is I. hydrogen or alkyl of 1 to 4 carbon atoms in the 2,3,6 or 7 position, or Ii. chlorine or bromine, in the 2, 3 or 7 position, Iii. nitro or --NHA wherein A is alkanoyl of 1 to 4 carbon atoms, in the 2, 3 or 7 position, or Iv. fluorine, cyano or COOB, wherein B is alkyl of 1 to 4 carbon atoms, in the 2 or 3 position, and R2 is I. hydrogen or alkyl of 1 to 4 carbon atoms in the 2, 3, 6 or 7 position, Ii. chlorine or bromine, in the 2, 3 or 7 position, or Iii. fluorine in the 2 or 3 position, useful in the treatment of heart diseases.
